Charles River expands strategic partnership with SAMDI Tech

By The Science Advisory Board staff writers

January 28, 2022 -- Charles River Laboratories has expanded its strategic partnership with SAMDI Tech. The expanded agreement will provide Charles River's clients seamless access to the label-free, high-throughput screening mass spectrometry (MS) platform in drug discovery.

Under the existing partnership, established in 2018, SAMDI Tech clients have access to Charles River's collection of lead-like compounds for high-throughput screening.

SAMDI's technology combines self-assembled monolayers and matrix-assisted laser desorption/ionization (MALDI) MS and addresses the throughput and sample preparation limitations of traditional MS screening methods. The combination of Charles River's end-to-end portfolio and scientific bench with SAMDI Tech's innovative technology and expertise in assay solutions has the potential to significantly accelerate and augment clients' discovery efforts by measuring biochemical activities and binding events for virtually any target, according to the firms.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts.

Charles River, Valo Health announce strategic partnership
Charles River Laboratories and Valo Health have formed a multiyear strategic partnership to offer a transformative, artificial intelligence-enabled drug...
Charles River to partner with ATEM Structural Discovery
Charles River Laboratories International has inked a partnership with ATEM Structural Discovery to provide its clients with ATEM's cryoelectron microscopy...
Charles River reports 34% revenue spike in Q2
Charles River Laboratories reported a 34% increase in revenue for the second quarter of 2021 compared to the same period during the previous year.
Charles River to acquire Vigene Biosciences for $293M
Charles River Laboratories has entered into an agreement to acquire Vigene Biosciences, a U.S-based gene therapy contract development and manufacturing...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter